Skip to main content

Table 3 Changes in OCS use (dosage expressed as prednisone-equivalent) during treatment with benralizumab

From: ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study

Variable

Evaluable N = 44

Starting dose ≤ 5 mg/die (N = 14)

Starting dose > 5 mg/die (N = 30)

Any reduction

22 (50%)

8 (57.1%)

14 (46.7%)

Reduction from baseline

 100%

19 (43.2%)

6 (42.9%)

13 (43.3%)

 ≥ 90%

19 (43.2%)

6 (42.9%)

13 (43.3%)

 ≥ 75%

20 (45.5%)

6 (42.9%)

14 (46.7%)

 ≥ 25%

21 (47.7%)

7 (50%)

14 (46.7%)

No reduction

22 (50%)

6 (42.9%)

16 (53.3%)

  1. Data are expressed as frequencies (N [%])